key: cord-0714499-y2f3r9f8
authors: Ong, Sean Wei Xiang; Young, Barnaby Edward; Lye, David Chien
title: Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes
date: 2021-04-12
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00201-2
sha: e1da6a79f3d659460ba4eeb23c9c0795b2efe192
doc_id: 714499
cord_uid: y2f3r9f8

nan

The SARS-CoV-2 lineage B.1.1.7 is characterised by a suite of defining mutations in the immunodominant spike protein, including a signature Asp501Tyr substitution in the receptor-binding domain. 1 First reported in December 2020, in the UK, the variant's discovery coincided with a substantial surge in case numbers and fatalities in the UK, raising concerns that this variant was both more infectious and virulent than previous variants. Epidemiological and modelling studies have yielded good evidence that B.1.1.7 is more transmissible than other variants. 1,2 However, conclusions as to the effects of B.1.1.7 on disease severity are less certain. Confounding factors including healthcare resource use, demographic changes, and sociobehavioural trends affect clinical outcomes, including mortality, and are difficult to adjust for without detailed, robust, patient-level data.

In The Lancet Infectious Diseases, Dan Frampton and colleagues 3 report their findings from such a study.

Analysing a cohort of 341 patients, including 198 (58%) with B.1.1.7 infections, the authors correlated outcomes with granular clinical data. Their observation that B.1.1.7 infections were associated with increased viral loads corroborates findings from two other studies 4, 5 and provides a mechanistic hypothesis that increased transmissibility is via increased respiratory shedding. Yet, disease severity and clinical outcomes between patients with B.1.1.7 and non-B.1.1.7 infections were similar after adjusting for differences in age, sex, ethnicity, and comorbidities. Importantly, this study was done from Nov 9, to Dec 20, 2020, before the late-December peak in UK COVID-19 infections, avoiding any confounding effect of the availability of health-care resources on mortality.

This finding is in contrast with three studies that reported increased mortality associated with lineage B.1.1.7 (table). [6] [7] [8] Several factors might explain this discordance. Two of these studies were based on a Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes Frampton et al 3 Challen et al 6 Davies et al 7 community-based testing dataset, whereas Frampton and colleagues studied a cohort of patients admitted to hospital, which included substantially more older adults than the other studies did. Although the proportion of patients with severe illness was not reported by the other studies, this proportion was probably much lower than that in Frampton and colleagues' study. Hence, although these large community studies found a significant difference in mortality at a population level, the absolute risk increase affecting individual patients is probably minimal. Furthermore, instead of whole-genome sequencing as used by Frampton and colleagues, these studies used S-gene target failure (SGTF) on PCR assay as a surrogate measure for detection of lineage B.1.1.7. The B.1.1.7 variant is associated with nucleotide deletions that prevent S gene target amplification by several commercial tests. This method gave rise to notable selection bias because S-gene data were unavailable in certain areas because of assay availability, with half of patients in both studies having unknown S gene status. Crucially, missing SGTF status was associated with older age and place of residence, with most patients in care homes having absent S-gene data, where mortality rates from COVID-19 are highest.

Thus, although limited by a much smaller dataset, the study by Frampton and colleagues has important advantages over the three community studies. These advantages include the use of whole-genome sequencing, recruitment of hospitalised patients, and a population reflective of the spectrum of severity in whom increased virulence will have the greatest effect on outcomes. The finding that lineage B.1.1.7 infection did not confer increased risk of severe disease and mortality in this high-risk cohort is reassuring but requires further confirmation in larger studies.

These differences between B.1.1.7 and non-B.1.1.7 lineages mirror those of other virological sub-groups of SARS-CoV-2. Similarly conflicting data was initially reported when variants carrying the Asp614Gly substitution emerged and became the dominant variants worldwide over the first few months of the pandemic in 2020. Early population-level data suggested that this substitution was associated with increased COVID-19 mortality but later cohort studies found no effect on disease severity. 9, 10 In a study we did in Singapore comparing different SARS-CoV-2 clades, Asp614Gly was associated with increased viral loads without changes in severity or transmission. 11 Genetic drift and selection pressures (in particular with passive antibody treatments and vaccination) will continue to engender changes in SARS-CoV-2 and might result in the emergence of variants of high consequence-variants that are more virulent, escape from host immunity, or are resistant to treatment. Active, timely, and broad-based genomic surveillance is crucial for their early detection. But careful epidemiologic and clinical assessment, coupled with a healthy scepticism, is important when assessing claims of the effect of these variants.

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a wholegenome sequencing and hospital-based cohort study

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR

Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England

Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?

Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: an observational study